drugset / Trial / NCT04633057
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase III, Randomized, open-label, positive-drug parallel control, Study to Evaluate the Efficacy and Safety of TJ101 in Child subject with growth hormone deficieney.
Timeline
- Start
- 2021-01-25
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NordiFlex | Protein / enzyme biologic | 0.034 mg/kg | — |
| Subject | TJ101 | Protein / enzyme biologic | 1.2 mg/kg | — |